Gilead (Kite) Partners with COTA to Accelerate Clinical Development Using Real-World Data
On Tuesday, March 16, Gilead (Kite) announced a collaboration with COTA (press release), a real-world data (RWD) analytics company, to accelerate Gilead’s oncology CAR-T pipeline. Of note, COTA could provide valuable insights into clinical trial design and perhaps future therapeutic applications. Below, Celltelligence provides insights on how Gilead (Kite) could leverage COTA’s data to strategically accelerate promising clinical assets, as well as similar RWD partnerships for BMS, Novartis, and Tmunity.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.